Edition:
United States

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

10.27USD
12:48pm EST
Change (% chg)

$0.32 (+3.27%)
Prev Close
$9.95
Open
$9.95
Day's High
$10.30
Day's Low
$9.95
Volume
44,840
Avg. Vol
160,031
52-wk High
$13.15
52-wk Low
$4.85

Select another date:

Wed, Nov 8 2017

BRIEF-Neos Therapeutics reports Q3 loss of $0.58/shr

* Neos Therapeutics reports third quarter 2017 financial results

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

BRIEF-Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA

* Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.

CORRECTED-Neos Therapeutics to consider other offers after PDL snub -sources

Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.

BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma

* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​

BRIEF-PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share

* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash

BRIEF-Neos therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

BRIEF-Neos Therapeutics receives U.S. FDA approval

* Neos Therapeutics receives U.S. FDA approval of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older

BRIEF-Neos Therapeutics announces launch of Cotempla XR-OD extended-release orally disintegrating tablets for treatment of ADHD

* Neos Therapeutics announces launch of Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets for the treatment of ADHD in patients 6 to 17 years old Source text for Eikon: Further company coverage:

Select another date: